Solutions at the speed of now

In the recent Law360 article, “FDA Cuts Prompt Biotech Players to Rethink Deal Strategies,” Marc Alcser, chair of the life sciences group at Stradling Yocca, shared his concerns about the impact of FDA staff cuts on the biotech industry. He noted that the cuts' implementation, likened to a "hammer approach" rather than a precise "knife approach," is causing uncertainty, as "nobody really knows what the impact will be yet." Alcser emphasized the FDA's crucial role as the "critical gatekeeper" for biotech companies, and that delays in FDA reviews and approvals could have a severe impact in the sector, particularly for smaller companies with limited cash reserves.

Ryan Gaglio was interviewed by Law360 regarding safe harbors proposed by the IRS. The article discusses the IRS’ proposed new safe harbors aimed at offering certain corporate spinoffs statutory tax-free treatment. This proposal comes in the wake of previous guidance that faced criticism for its restrictive nature, and while the new rules offer more leniency, they still demand careful navigation due to the complexities inherent in each spinoff transaction. 

On March 20, 2025, the Equal Employment Opportunity Commission (EEOC) issued two key pieces of guidance regarding DEI: What To Do If You Experience Discrimination Related to DEI at Work and What You Should Know About DEI-Related Discrimination at Work. It is crucial for employers to understand the potential implications of DEI programs and initiatives, and these pieces of guidance provide insight into what has changed and what the EEOC will be monitoring.